Company intelligence / Profile preview

Nu-Med Plus

Port Jefferson, New York, United Statesnu-medplus.org ↗

Ownership: Private
Employees: ~2
Development stage: Commercial

Overview

Nu-Med Plus has developed a suite of medical devices designed to generate and deliver precision doses of inhaled nitric oxide. The company’s technology aims to address unmet needs in critical care settings such as neonatal intensive care units and emergency medicine. Clinical trials have been conducted or are ongoing for applications including COVID-19-related ARDS. The company has also filed patents related to wound care applications using aqueous nitric oxide solutions.

Therapeutic areas: PulmonologyDermatologyCardiovascularInfectious Diseases
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

No major pharmaceutical partnerships publicly disclosed; reports interest from international physicians/distributors/potential strategic partners

Beyond the preview

Go deeper on Nu-Med Plus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nu-Med Plus.

Explore the full profile